LC-SF-14

CAT: 0804-HY-172916Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-172916Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR (IC50 values are 71.6 and 8.9 nM, respectively) . LC-SF-14 inhibits FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation. LC-SF-14 inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM) . LC-SF-14 has antitumor activity in the SNU-16 xenograft mouse model. LC-SF-14 can be used in FGFR2-driven gastric cancer research[1].
UNSPSC
12352211
Target
ERK; FGFR; p38 MAPK; SHP2
Related Pathways
MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer
Smiles
O=C(NC1=CC=CC(SC2=NC=C(N3CCC(C)(N)CC3)N=C2N)=C1Cl)CCC(N4CCN(C5=CC=C(NC6=NC=NC(N(C)C(NC7=C(Cl)C(OC)=CC(OC)=C7Cl)=O)=C6)C=C5)CC4)=O
Molecular Formula
C44H50Cl3N13O5S
Molecular Weight
979.38
References & Citations
[1]Zheng L, et al. Discovery of LC-SF-14, a selective dual inhibitor of SHP2 and FGFR for the treatment of FGFR2-driven gastric cancer. Eur J Med Chem. 2025 May 11;294:117745.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products